Iopamidol in lumbar myelography.
Iopamidol is a new, nonionic, water-soluble contrast material currently undergoing clinical trials for intravascular and intrathecal use in Europe and the United States. In this study, 12 patients underwent lumbar myelography with this agent. For each subject, up to 12 mL of iopamidol (at 200 mg I/mL) was employed. The myelograms obtained were highly satisfactory. No serious adverse reactions were observed. The most common side effect--headache--occurred in seven patients. However, six of the seven headaches were mild and transient, and did not require treatment. Nausea occurred in two patients, back pain in two patients, hypotension and hypertension each in one patient. All of these reactions were mild and self-limited. Iopamidol appears to be a safe and conveniently used agent for lumbar myelography.
D000328:Adult; D000368:Aged; D001416:Back Pain / Q000209:etiology; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007278:Injections, Spinal; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging; D007479:Iopamidol; D007483:Iothalamic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008159:Lumbar Vertebrae; D008297:Male; D008875:Middle Aged; D009192:Myelography / Q000379:methods*; D009325:Nausea / Q000139:chemically induced
D007483:Iothalamic Acid; D007479:Iopamidol